Capsule maker calls for deglobalization of pharma manufacturing in U.S.
CapsCanada, a provider of two-piece empty capsules serving the global pharmaceutical industry, is bringing attention to U.S. reliance on foreign pharmaceutical ingredients, highlighted by the global COVID-19 pandemic.
Unchained Labs launches new gene therapy tool
Unchained Labs has launched a new gene therapy quantification application on Stunner, its gene therapy platform.
Avrobio expands Hunter syndrome gene therapy program
Avrobio has signed a research and licensing agreement with the University of Manchester in the U.K. to investigate the use of lentiviral gene therapy for mucopolysaccharidosis type II, aka Hunter syndrome.
BioMarin receives fast track designation for PKU gene therapy
The U.S. Food and Drug Administration has granted BioMarin Pharmaceutical fast track designation for BMN 307, an investigational gene therapy drug for the treatment of individuals with phenylketonuria (PKU).
10 ways to promote antiracism in research environments
A pair of laboratory scientists has proposed 10 ways principal investigators and group leaders can cultivate antiracist research environments.
Gamma Biosciences acquires Nanopareil
Gamma Biosciences has purchased nanofiber membrane product developer Nanopareil.
Ionis, Genuity Science partner to advance RNA-targeted therapies
Ionis Pharmaceuticals and Genuity Science have entered a multiyear collaboration to accelerate the discovery and development of genetically validated targets for up to 20 diseases.
RNA targeting could prevent replication of SARS-CoV-2 virus
What if you could stop the SARS-CoV-2 virus from reproducing itself? Researchers from Florida hope to do just that by creating a compound that targets and binds to RNA regions on the SARS-CoV-2 genome and disrupts its replication. The research was described in a September 30 article published in ACS Central Science.  Discuss
CRB introduces multimodal facility to support cell & gene therapy clients
CRB has created SlateXpace, a multimodal manufacturing facility solution to support complex therapeutic product pipelines.
Regenxbio expands clinical development for Hunter syndrome gene therapy
Regenxbio has expanded its RGX-121 gene therapy program for the treatment of mucopolysaccharidosis type II (Hunter syndrome) to evaluate the product in a broader patient population.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter